Savant Capital LLC Buys 259 Shares of Natera, Inc. (NASDAQ:NTRA)

Savant Capital LLC lifted its position in Natera, Inc. (NASDAQ:NTRA) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,933 shares of the medical research company’s stock after buying an additional 259 shares during the quarter. Savant Capital LLC’s holdings in Natera were worth $2,997,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Creative Planning grew its position in shares of Natera by 28.3% during the 2nd quarter. Creative Planning now owns 4,929 shares of the medical research company’s stock valued at $534,000 after purchasing an additional 1,087 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in Natera during the second quarter worth about $380,000. GAMMA Investing LLC increased its stake in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after acquiring an additional 106 shares during the last quarter. CWM LLC boosted its position in shares of Natera by 119.5% during the 3rd quarter. CWM LLC now owns 15,441 shares of the medical research company’s stock valued at $1,960,000 after acquiring an additional 8,406 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Natera by 30.5% during the third quarter. Exchange Traded Concepts LLC now owns 12,064 shares of the medical research company’s stock worth $1,532,000 after purchasing an additional 2,821 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Performance

Natera stock opened at $169.71 on Wednesday. Natera, Inc. has a 1-year low of $67.33 and a 1-year high of $183.00. The firm has a market cap of $22.41 billion, a P/E ratio of -96.43 and a beta of 1.66. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average of $167.72 and a 200-day moving average of $141.94.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter last year, the business posted ($0.95) EPS. The business’s revenue was up 63.9% on a year-over-year basis. Sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on NTRA shares. Craig Hallum lifted their target price on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Piper Sandler upped their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Barclays began coverage on Natera in a report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their target price on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $165.88.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,728 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48. Following the transaction, the chief executive officer now directly owns 185,034 shares of the company’s stock, valued at approximately $27,090,827.94. The trade was a 2.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Fesko sold 663 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 312,394 shares of company stock worth $52,333,520 over the last quarter. 7.60% of the stock is owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.